189 related articles for article (PubMed ID: 36762057)
21. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Germonpré P; Van den Wyngaert T
PLoS One; 2019; 14(4):e0215135. PubMed ID: 30973926
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients.
Lv J; Zhang W; Deng R; Chen Y; Liu M; Zhang Z; Wang Q; He Y; Liu Y; Wang F; Lv Z; Zhou H; Li C; Zhang T; Fu Y; Zhao X; Bao Q; Miao Y; Wang L; Huang M; Zhang C
J Clin Pharm Ther; 2022 Aug; 47(8):1257-1263. PubMed ID: 35397125
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Li XP; Zhang WD; Li MJ; Wang J; Lian J; Zhou HG
J Oncol; 2022; 2022():1710272. PubMed ID: 35909903
[TBL] [Abstract][Full Text] [Related]
24. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Jul; 9(7):805-813. PubMed ID: 29768721
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
Karadurmus N; Kaplan MA; Sendur MAN; Urun Y; Demirci U; Karaca SB; Goktas Aydin S; Aykan MB; Bilici A; Sezer A; Yilmaz U; Abali H; Yumuk PF; Degirmencioglu S; Demirkazik A; Paydas S; Mirili C; Turna H; Kargi A; Ozdogan M; Guven DC; Ozguroglu M; Kilickap S
Curr Med Res Opin; 2024 Jun; ():1-8. PubMed ID: 38809230
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
Front Oncol; 2022; 12():816198. PubMed ID: 35982962
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
28. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy: A retrospective analysis.
Huang W; Zhang Q; Da L; Shen Y; Xiong F; Zhang C
J Cancer Res Ther; 2022 Apr; 18(2):576-580. PubMed ID: 35645130
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
[TBL] [Abstract][Full Text] [Related]
31. Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study.
Zhao YN; Cong D; Zhang W; Jia Y; Bai Y
J Gastrointest Oncol; 2023 Apr; 14(2):733-743. PubMed ID: 37201088
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.
Zhang D; Kong F; Gao F; Li L; Liang Y; Yu M; Zhao L; Wang N; Jia Y
Heliyon; 2024 Jan; 10(1):e22913. PubMed ID: 38148793
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
34. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
35. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
36. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.
Liu C; Yu H; Long Q; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Chang J; Wang J
Front Oncol; 2019; 9():1116. PubMed ID: 31696059
[No Abstract] [Full Text] [Related]
37. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
38. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
39. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
